Leviliv 500 Tablet contains Levetiracetam 500 mg, an antiepileptic medication primarily indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, which contributes to its anticonvulsant effects. This mechanism helps to stabilize neuronal activity and prevent seizure propagation. Leviliv 500 is typically administered orally, with dosage individualized based on patient age, renal function, and clinical response. It is well tolerated, with common adverse effects including somnolence, dizziness, headache, and fatigue, which are generally mild to moderate in intensity. Caution is advised in patients with renal impairment, and dose adjustments may be necessary. Leviliv 500 should be used under medical supervision, and abrupt discontinuation should be avoided to prevent seizure exacerbation. It is important to monitor for any neuropsychiatric symptoms such as mood changes or depression during therapy. Leviliv 500 Tablet is a valuable option in epilepsy management, offering efficacy and a favorable safety profile when used as monotherapy or adjunctive therapy.